Sun Pharmaceutical Industries vs Lupin: Which Stock Should You Track

July 31, 2026
Posted by: Ankit Jaiswal
Category: Mutual Funds

Sun Pharmaceutical Industries vs Lupin: India’s largest pharmaceutical company by market cap vs a leading Indian pharmaceutical company in respiratory and cardiovascular generics. Sun Pharmaceutica…

Sun Pharmaceutical Industries vs Lupin is a comparison investors search for because the two companies represent genuinely different positions within Pharmaceuticals. This Sun Pharmaceutical Industries vs Lupin breakdown goes beyond generic labels and looks at real numbers: reach, products, the latest results each company has declared, and how each stock is positioned today. Understanding Sun Pharmaceutical Industries vs Lupin this way is more useful than a surface-level label, because it shows where each company actually stands rather than how it describes itself.

Table of Contents

Sun Pharmaceutical Industries vs Lupin: Reach and Market Position

In the Sun Pharmaceutical Industries vs Lupin comparison, Sun Pharmaceutical Industries stands out for India’s largest drugmaker by market cap, with a growing specialty pharmaceuticals franchise alongside its generics business. This scale gives Sun Pharmaceutical Industries a distinct position within Pharmaceuticals that shapes how it competes.

Click Here – Get Free Investment Predictions

Lupin, on the other hand, is built around a Mumbai-based pharmaceutical company with a strong presence in respiratory, cardiovascular and anti-diabetic therapies across India, the US and other global markets. Comparing Sun Pharmaceutical Industries vs Lupin on reach alone shows two different growth strategies, not a single verdict.

Sun Pharmaceutical Industries vs Lupin: Key Products and Business Mix

Sun Pharmaceutical Industries’s business runs on generic drugs, specialty pharmaceuticals (including the Ilumya brand), and active pharmaceutical ingredients. This product mix is central to any Sun Pharmaceutical Industries vs Lupin comparison, since it explains where each company’s revenue actually comes from.

Lupin instead leans on generic and branded formulations across respiratory, cardiovascular, anti-diabetic and anti-infective therapy areas. The Sun Pharmaceutical Industries vs Lupin product comparison shows these are genuinely different businesses, not just different brand names in the same category.

Sun Pharmaceutical Industries vs Lupin: Latest Results

Looking at real numbers rather than claims, Sun Pharmaceutical Industries’s latest disclosed results show Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth with profit expected to decline 7-11% YoY on margin pressure from higher input costs. This is the clearest evidence available for the Sun Pharmaceutical Industries vs Lupin comparison on Sun Pharmaceutical Industries’s side.

Lupin’s latest disclosed results show Positioned by the market among India’s larger generics exporters, with growth tied to US generic approvals and India branded formulation sales. Weighing Sun Pharmaceutical Industries vs Lupin on actual results, rather than headline positioning, is what separates a useful comparison from a generic one.

Compare Sun Pharmaceutical Industries and Lupin Fundamentals on the Univest Screener

Sun Pharmaceutical Industries vs Lupin: Stock and Valuation

On the market side, Sun Pharmaceutical Industries is described as: Market cap around Rs 4,32,036 crore. Lupin is described as: Tracked alongside Sun Pharma, Dr Reddy’s, Cipla and Aurobindo Pharma as one of India’s major listed pharma companies. The Sun Pharmaceutical Industries vs Lupin valuation gap often reflects how the market is pricing each company’s growth and risk profile differently.

Sun Pharmaceutical Industries vs Lupin: Quick Comparison Table

Parameter	Sun Pharmaceutical Industries	Lupin
Sector	Pharmaceuticals	Pharmaceuticals
Market position	India’s largest pharmaceutical company by market cap	a leading Indian pharmaceutical company in respiratory and cardiovascular generics
Reach	India’s largest drugmaker by market cap, with a growing specialty pharmaceuticals franchis	a Mumbai-based pharmaceutical company with a strong presence in respiratory, cardiovascula
Latest results	Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth w	Positioned by the market among India’s larger generics exporters, with growth tied to US generic app

Conclusion

Sun Pharmaceutical Industries vs Lupin ultimately comes down to two companies solving similar problems in different ways. Sun Pharmaceutical Industries brings India’s largest pharmaceutical company by market cap, while Lupin brings a leading Indian pharmaceutical company in respiratory and cardiovascular generics. Investors weighing Sun Pharmaceutical Industries vs Lupin should track both companies’ upcoming results and valuation gap rather than picking a side on reputation alone. This Sun Pharmaceutical Industries vs Lupin breakdown is a starting point, not a final verdict.

Download the Univest iOS App or Univest Android App to track Sun Pharmaceutical Industries and Lupin live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What is the main difference between Sun Pharmaceutical Industries and Lupin?

Ans. The main difference in the Sun Pharmaceutical Industries vs Lupin comparison lies in scale and business mix. Sun Pharmaceutical Industries is built on India’s largest pharmaceutical company by market cap, while Lupin is positioned around a leading Indian pharmaceutical company in respiratory and cardiovascular generics.

How do Sun Pharmaceutical Industries and Lupin’s latest results compare?

Ans. Comparing Sun Pharmaceutical Industries vs Lupin on latest disclosed results: Sun Pharmaceutical Industries reported Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth with profit expected to decline 7-11% YoY, while Lupin reported Positioned by the market among India’s larger generics exporters, with growth tied to US generic approvals and India branded formulation sal.

What sector do Sun Pharmaceutical Industries and Lupin operate in?

Ans. Sun Pharmaceutical Industries operates in Pharmaceuticals and Lupin operates in Pharmaceuticals. Even where the sectors overlap, the Sun Pharmaceutical Industries vs Lupin comparison shows different product mixes and market positions.

Should I invest in Sun Pharmaceutical Industries or Lupin?

Ans. Both Sun Pharmaceutical Industries and Lupin have distinct strengths within their space. Investors comparing Sun Pharmaceutical Industries vs Lupin should review the latest quarterly results, valuation and their own risk profile, and consult a financial advisor before deciding.

What are the key products of Sun Pharmaceutical Industries?

Ans. Sun Pharmaceutical Industries’s key products and business lines include generic drugs, specialty pharmaceuticals (including the Ilumya brand), and active pharmaceutical ingredients.

What are the key products of Lupin?

Ans. Lupin’s key products and business lines include generic and branded formulations across respiratory, cardiovascular, anti-diabetic and anti-infective therapy areas.

How do Sun Pharmaceutical Industries and Lupin compare on market position?

Ans. On market position, Sun Pharmaceutical Industries holds India’s largest pharmaceutical company by market cap, while Lupin holds a leading Indian pharmaceutical company in respiratory and cardiovascular generics. The Sun Pharmaceutical Industries vs Lupin comparison shows both companies lead in different ways rather than one being universally ahead.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.